Biogen schedules October 28 results. Biogen stock trades 0.62 percent below its 52-week high

Published on 10/27/2026 at 19:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 2.736 billion. Biogen stock costs EUR 226.70 on October 27, 2026, while USD 252.83 is 0.62 percent below USD 254.41.

Reporting date and operating facts

Biogen scheduled its third-quarter results for October 28, 2026.
Second-quarter revenue reached USD 2.736 billion and diluted earnings per share were USD 0.66.
Biogen stock costs EUR 226.70 at Lang & Schwarz on October 27, 2026 at 7:20 p.m. CEST.

Biogen Inc., US09062X1037, Illustration mit AI erstellt.

Biogen Inc. (ISIN US09062X1037) has scheduled its third-quarter results for October 28, 2026, with the date reported by Investing.com. On October 27, 2026, Biogen stock stood at USD 252.83 on the Nasdaq, 0.62 percent below its 52-week high of USD 254.41. Biogen was trading at EUR 226.70 at Lang & Schwarz on October 27, 2026 at 7:20 p.m. CEST.

Second-quarter revenue reached USD 2.736 billion

Biogen reported USD 2.736 billion in revenue for the second quarter of 2026, up 10.42 percent from USD 2.4778 billion in the first quarter. Diluted earnings per share were USD 0.66, while net income attributable to common shareholders reached USD 97.5 million in the second quarter.

Operating cash flow totaled USD 448.9 million in the second quarter, down from USD 645.5 million in the first quarter. The sequential comparison matters because the revenue increase did not translate into a higher quarterly net result.

USD 254.41 high sets the frame

The Nasdaq quotation was 0.62 percent below the 52-week high and stood above the 52-week low of USD 138. Trading volume was 431,972 shares on October 27, 2026. Biogen's market capitalization was USD 37.4 billion, and its price-to-earnings ratio was 44.74.

On October 22, 2026, BofA Securities raised its price target for Biogen from USD 219 to USD 244 while maintaining a Neutral rating, Investing.com reported. The target is 3.50 percent below the Nasdaq price of USD 252.83 on October 27, 2026, keeping the upcoming report as the next concrete test for the valuation.

Analyst breadth remains a key comparison

CNBC reported on October 12, 2026 that 26 of 38 analysts covering Biogen held Buy or Strong Buy ratings. That figure provides a quantified counterpoint to BofA's Neutral stance before the October 28 results.

Results date comes next

The October 28, 2026 reporting date is the next scheduled company event. For investors, the useful comparison will be whether revenue growth and operating cash flow can improve together after the second-quarter gap between the two measures.

The further course of trading is shown by the continuously updated real-time quote of Biogen stock.